Neogap strengthens global IP position with Chinese patent for T cell expansion method
Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has been granted a Chinese patent for its method of expanding tumour-specific T cells – a key component of the company’s therapeutic approach. The grant strengthens Neogap’s international IP position and supports its long-term strategy to protect and advance its proprietary technologies globally.[Neogap-Therapeutics-secures-patent-China.png]
The Chinese patent covers a process used to produce Neogap’s personalised cell-based immunotherapy, pTTL, which is currently under evaluation in a
